Treatment failure and relapse are common in diseases of chronic inflammation, and psoriasis is no exception.

The Food and Drug Administration (FDA) has granted accelerated approval to Ojemda ™ (tovorafenib) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) ...

For patients with relapsed or refractory CD7-positive leukemia or lymphoma, sequential CD7 chimeric antigen receptor (CAR) ...

Netherlands: A recent study published in the online issue of Neurology, the medical journal of the American Academy of ...

Ojemda is the first systemic therapy approved by the FDA for the treatment of relapsed or refractory pediatric low-grade ...

Infusions of ketamine are an effective, safe, and well tolerated option for severe, refractory headache in children, ...

It represents the first systemic therapy for pediatric low-grade gliomas harboring BRAF rearrangements, or fusions, according ...

Patrick Andre, Chief Executive Officer, Vesuvius Group, highlighted the promising growth scenario in India, stating that the ...

The FDA granted accelerated approval to tovorafenib (Ojemda) to treat patients with relapsed or refractory BRAF -altered ...

The FDA on Tuesday approved Day One Biopharmaceuticals’ type II RAF inhibitor Ojemda, which is designed to penetrate the ...

The investigational drug ziftomenib is currently being evaluated for patients with relapsed/refractory NPM1-mutant acute ...

Binod Dhakal, MD, associate professor, Medical College of Wisconsin, is lead investigator of the CARTITUDE-4 study, from ...